Evelyn Fahrenkrug
Global Commercial Head Oncology Pipeline Boehringer Ingelheim
Evelyn Fahrenkrug is an accomplished executive in commercial strategy and lifecycle management, currently serving as Global Head of Commercial Pipeline in Oncology at Boehringer Ingelheim. She is dedicated to driving competitive value creation across the pipeline portfolio, with a focus on shaping strategic direction and maximizing long-term impact.
Evelyn has consistently demonstrated outstanding leadership across global and regional roles, successfully guiding cross-functional teams through complex product launches and organizational transformations. Her ability to lead in dynamic environments has resulted in sustained growth, operational excellence, and strategic innovation. Previous roles at Boehringer Ingelheim include Regional Head of Specialty Care, General Manager, and Global Asset Lead in Oncology, where she delivered measurable results and built high-performing teams across diverse markets.
Seminars
- Antibody–drug conjugates are one of oncology’s most promising modalities — delivering potent, targeted therapy more selectively than conventional chemotherapy across the patient journey
- But success is scientifically demanding, depending not on the target alone but on the disciplined integration of biology, engineering and patient selection
- Outlining the critical success factors underpinning ADC development, highlighting how a holistic, end-to-end strategy can maximise clinical efficacy, improve safety, and unlock the full therapeutic potential of next-generation ADCs and making it an attractive investment opportunity
- Outlining the latest trends across the ADC landscape in 2027 and future vision to develop and deliver novel ADCs with meaningful patient impact with safety and efficacy
- Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
- With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?
